Hepatic Adenoma Associated with Recombinant Human Growth Hormone Therapy in a Patient with Turner’s Syndrome

2000 ◽  
Vol 17 (6) ◽  
pp. 640-643 ◽  
Author(s):  
Joseph Espat ◽  
Ronald S. Chamberlain ◽  
Charles Sklar ◽  
Leslie H. Blumgart
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Therapy ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Turner's Syndrome ◽  
Hepatic Adenoma ◽  
Turner’S Syndrome

Growth-Stimulating Effects of Human Growth Hormone Therapy in Turner’s Syndrome

1986 ◽  
pp. 109-113 ◽  
Author(s):  
Salvatore Raiti ◽  
S. L. Kaplan ◽  
G. P. August ◽  
S. A. Kaplan ◽  
M. H. MacGillivray ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Therapy ◽  
Human Growth ◽  
Turner's Syndrome ◽  
Turner’S Syndrome

scholarly journals Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Jing Wu ◽  
Fei Zhao ◽  
Yuan Zhang ◽  
Jiang Xue ◽  
Jiangying Kuang ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Treatment ◽  
Growth Hormone Therapy ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Hormone Treatment ◽  
Risk Markers ◽  
One Year

It has been recognized that people with obesity are more likely to have low growth hormone secretion. Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity. However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children. This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity. Eighteen boys with obesity were treated with recombinant human growth hormone for one year. Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively. After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P<0.001) and insulin-like growth factor 1 levels increased (P<0.001). GH treatment also reduced low density lipoprotein cholesterol (P<0.001), total cholesterol (P<0.001), triglycerides (P=0.042), and alanine aminotransferase (P=0.027) when compared with the baseline. One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.

Ileal perforation in a patient with Crohn’s disease while receiving recombinant human growth hormone therapy

2006 ◽  
Vol 22 (8) ◽  
pp. 983-984 ◽  
Author(s):  
Gernot W. Wolkersdörfer ◽  
Stephan Miehlke ◽  
Ralph Schneider ◽  
Gerhard Ehninger ◽  
Ingolf Schiefke ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Therapy ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Ileal Perforation

scholarly journals Effects of short‐term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients

2002 ◽  
Vol 17 (2) ◽  
pp. 260-264 ◽  
Author(s):  
Pedro Iglesias ◽  
Juan José Díez ◽  
Ma José Fernández‐Reyes ◽  
Mc Auxiliadore Bajo ◽  
Abelardo Aguilera ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Human Growth Hormone ◽  
Growth Hormone Therapy ◽  
Recombinant Human Growth Hormone ◽  
Human Growth ◽  
Dialysis Patients ◽  
Short Term ◽  
Plasma Leptin
Sign in / Sign up

Export Citation Format

Share Document